Katan Associates International

What Katan Associates International does

Katan Associates International is a corporate strategy and merchant banking firm focused exclusively on the Life Sciences sector, founded in 2001 and headquartered in Manhattan Beach, California. The firm targets sub-$50 million revenue companies in therapeutics, diagnostics, devices, and lab supply/reagents, with offices in Los Angeles, Israel, and Australia. Its service model differentiates from traditional consulting through operational involvement: co-founder Seth Yakatan and the partner team of approximately five named professionals take an implementation and occasionally managerial role in client strategy, rather than delivering pure advisory evaluations.

The firm's revenue is generated across four professional-services and investment streams: strategic consulting retainers, mergers & acquisitions advisory for sub-$50M Life Sciences targets, partnering transactions leveraging relationships with global pharma and biotech companies, and merchant banking — direct investment positions in portfolio companies, sometimes coupled with operational executive roles. Engagement follows a mandate-based, face-to-face evaluation process centered on management quality, sustainable competitive advantage, shared value expectations, and identifiable value-add. The merchant banking capability is structural rather than episodic; principals act as direct investors, giving the firm exposure to portfolio upside alongside fee-based advisory revenue.

KAI's go-to-market is relationship-driven and non-institutional. No venture, private equity, or strategic investor backing is disclosed; ownership rests with the founding partners. Marketing channels are limited to the firm's Wix-hosted website and partner LinkedIn profiles. There is no published pricing, no software or technology product offering, no API or SDK distribution, and no public pipeline of financial milestones. Client engagement is selective — the firm works with 'a carefully selected group of clients each year,' which functions as a deliberate capacity constraint and a positioning signal rather than a growth lever.

Name

Katan Associates International

Legal name

Katan Associates International

Website

https://katanassociates.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Katan Associates International is a boutique corporate strategy and merchant banking firm serving Life Sciences companies with under $50 million in revenue across therapeutics, diagnostics, devices, and lab supply/reagents, with offices in California, Israel, and Australia.

Ownership category

akta.pro rank

Product category

Life Sciences Corporate Strategy & Merchant Banking

NAICS

Management, Scientific, and Technical Consulting Services (5416), Investment Banking and Securities Intermediation (523150), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Corporate Strategy Advisory (BPAHADAA)

akta.pro secondary industries

Corporate Development & Strategic Partnerships Advisory (JVs, Alliances, Carve-outs) (BPAHAOAG), Strategic Partnerships, Alliances & JVs Advisory (BPAHADAI), Corporate Finance & Capital Advisory (BPAHADAB)

Keywords

• Life sciences consulting
• Mergers acquisitions advisory
• Merchant banking services
• Corporate strategy advisory
• Biotech partnering transactions

Headquarters

HQ city

Manhattan Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Strategic Consulting: Long-term consulting engagements with carefully selected Life Sciences clients, providing operational and capitalization strategies.
2. Mergers & Acquisitions Advisory: M&A advisory services for Life Sciences companies with revenue under $50 million, specializing in therapeutics, diagnostics, device, and lab supply/reagents segments.
3. Partnering Transactions: Facilitation of partnering transactions between clients and global pharmaceutical and biotechnology companies.
4. Merchant Banking / Direct Investment: Katan Principals take managerial roles and act as direct investors in portfolio companies, with a track record of success in global pharmaceutical and biotechnology companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Katan Associates International delivers integrated corporate strategy and merchant banking services to Life Sciences companies with less than US$50 million in revenue. Core offerings include long-term strategic consulting with operational implementation, Mergers & Acquisitions advisory (focused on therapeutics, diagnostics, devices, and lab supply/reagents), Partnering Transaction facilitation with global pharmaceutical and biotechnology companies, and Merchant Banking with direct investment and managerial roles in portfolio companies.

Product overview

Katan Associates International offers a unified suite of corporate strategy and merchant banking services tailored for Life Sciences companies with less than US$50 million in revenue. The core offerings include consulting services (going beyond traditional strategic consulting to build long-term client partnerships), mergers and acquisitions advisory (with particular emphasis on therapeutics, diagnostics, devices, and lab supply/reagents segments), partnering services (leveraging relationships with global pharmaceutical and biotechnology companies), and merchant banking (direct investment and operational involvement in portfolio companies). These services are delivered as an integrated operational and capitalization strategy offering, rather than as discrete software products or technology modules.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategic Consulting Long-term, fully integrated consulting engagement for selected Life Sciences clients, going beyond a single evaluation or transaction to include deep understanding of management, technology, and financial position, followed by design and operational implementation of a fully integrated operational and capitalization strategy.
• Mergers & Acquisitions Advisory M&A advisory services for Life Sciences companies with less than US$50 million in revenue, with particular emphasis on the therapeutics, diagnostics, device, and lab supply/reagents segments.
• Partnering Transaction Services Facilitation of partnering transactions between selected Life Sciences clients and global pharmaceutical and biotechnology companies, leveraging Katan's relationships with numerous pharma/biotech counterparties.
• Merchant Banking / Direct Investment Direct investment in Life Sciences companies by Katan Principals, often with managerial or operational roles in portfolio companies, backed by a track record of success in several global pharmaceutical and biotechnology companies.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Locust Walk: Life sciences-focused advisory firm providing strategic consulting, M&A, and capital raising services to biotech and medtech companies. Directly comparable as a boutique Life Sciences advisory with overlapping M&A and partnering capabilities.
• Trinity Partners: Life Sciences-focused consulting firm providing strategy, market assessment, and transaction advisory to biotech and medtech companies. Directly comparable boutique Life Sciences consulting overlap.
• Health Advances: Strategy consulting firm focused exclusively on Life Sciences, providing commercial and strategic advice to therapeutics, diagnostics, and medical device clients. Directly comparable strategy consulting overlap for Katan's core advisory business.
• Torreya Partners: Global investment bank focused exclusively on Life Sciences M&A and strategic advisory. Closely comparable given the focus on pharma and biotech transactions across mid-market and emerging companies.
• PharmaVentures: Pharma advisory firm specializing in M&A, licensing, and partnering transactions across the global pharmaceutical and biotechnology sectors. Comparable for Katan's partnering transaction and cross-border pharma deal capabilities.
• Aquilo Partners: Life Sciences-focused investment bank specializing in M&A and capital raising for biotech, medtech, and diagnostics companies. Directly comparable in the boutique Life Sciences advisory niche with overlapping transaction sizes.
• Back Bay Life Science Advisors: Life Sciences-focused consulting and advisory firm supporting commercial strategy, due diligence, and transaction advisory for biotech and medtech companies. Directly comparable boutique Life Sciences advisory positioning.

Broad incumbents

• L.E.K. Consulting: Global strategy consulting firm with a substantial Life Sciences practice serving pharma, biotech, medtech, and diagnostics. Comparable as a Life Sciences strategy advisory competitor at greater scale and broader scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/SethYakatan

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Katan Associates International